Euroapi Full Year 2024 Earnings: EPS Misses Expectations

Euroapi (EPA:EAPI) Full Year 2024 Results

Key Financial Results

• Revenue: €919.2m (down 9.8% from FY 2023).
• Net loss: €130.6m (loss narrowed by 31% from FY 2023).
• €1.38 loss per share (improved from €2.01 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Euroapi EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 53%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 5.1% growth forecast for the Pharmaceuticals industry in France.

Performance of the French Pharmaceuticals industry.

The company's shares are down 15% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Euroapi has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.